News
Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...
In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...
Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...
The Senate Health, Education, Labor and Pensions Committee yesterday voted to advance a vote on President Donald Trump's ...
Vaccine maker Moderna announced today that the US Food and Drug Administration (FDA) has granted full approval of its ...
The full approval of Spikevax covers children aged six months through 11 years who are at increased risk for severe COVID-19, transitioning the vaccine from emergency use to full licensure.
12d
Stocktwits on MSNModerna’s Covid Vaccine Gets Full FDA Approval For Use In Children 6 Months And OlderModerna, Inc. (MRNA) on Thursday announced that the U.S. Food and Drug Administration (FDA) has fully approved its COVID-19 ...
The new memos from the Food and Drug Administration show how the agency’s vaccine chief, Dr. Vinay Prasad, personally intervened to place restrictions on COVID shots.
Those limits match the terms FDA recently approved for Novavax’s shot, Nuvaxovid and Moderna’s mNexspike. Novavax’s vaccine is the only protein-based coronavirus vaccine available in the U.S.
A top official at the Food and Drug Administration recently overruled government scientists on the availability of two ...
The new vaccine (mNexspike [COVID-19 Vaccine, mRNA]) represents a significant step forward in the development of next-generation coronavirus vaccines, the Associated Press reported.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results